The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer
- 215 Downloads
Epithelial ovarian cancer (EOC) is the most lethal cause of morbidity and mortality worldwide. miRNA deregulation evinces a remarkable role in ovarian cancer tumorigenesis. miRNA-199a (miR-199a) is known to be involved in cancer development and progression. Although miR-199a has been studied in various cell types, its correlation with clinicopathological features in EOC has not been documented. In this study, we identified the clinicopathological hallmarks which might be perturbed due to the downregulation of serum miR-199a in EOC. Seventy serum samples from histopathologically confirmed EOC patients and 70 controls were collected. Total RNA from serum was isolated by Trizol method, polyadenylated and reverse transcribed into cDNA. Expression level of miR-199a was detected by using miRNA qRT-PCR. Relative expression was determined with matched controls using U6 snRNA as reference. Level of miR-199a expression was compared with distinct clinicopathological features. Expression of miR-199a was found to be significantly downregulated in comparison with matched normal controls. The expression level of miR-199a was found to be significantly associated with tumor stage, lymph node metastasis, and distal metastasis. Receiver operating characteristic (ROC) curve for diagnostic potential yielded significant area under the curve (AUC) with a considerable sensitivity and specificity. ROC curves for prognosis yielded significant AUCs for histological grade, distal metastasis, lymph node status, and survival. Our findings suggest that miR-199a downregulation might be a potential indicator for disease progression promoting the aggressive tumor progression and be identified as a diagnostic marker to predict the prognosis and survival in EOC patients.
KeywordsEpithelial ovarian cancer microRNA-199a serum biomarker diagnosis prognosis
Epithelial ovarian cancer
Quantitative real-time polymerase chain reaction
We gratefully acknowledge the assistance of University Grants Commission for supporting this work.
Compliance with Ethical Standards
Conflicts of interest
Written informed consent was obtained from all individual participants included in the study.
All procedures performed in this study involving human participants were approved and were in accordance with the institutional ethics committee at Maulana Azad Medical College, New Delhi.
- 3.Guo W, Qiu Z, Wang Z, Wang Q, Tan N, Chen T, et al. MiR-199a-5p is negatively associated with the malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer. Hepatol Baltim Md. 2015 Jun 5.Google Scholar
- 9.Laval S, Butler R, Shelling AN, Hanby AM, Poulsom R, Ganesan TS. Isolation and characterization of an epithelial-specific receptor tyrosine kinase from an ovarian cancer cell line. Cell Growth Differ Mol Biol J Am Assoc Cancer Res. 1994;5(11):1173–83.Google Scholar
- 11.Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015 Jun 9.Google Scholar
- 12.Ge Q, Shen Y, Tian F, Lu J, Bai Y, Lu Z. Profiling circulating microRNAs in maternal serum and plasma. Mol Med Rep. 2015 Jun 3.Google Scholar
- 13.Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, et al. Serum miR-21, miR-29a and miR-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res Off J Am Assoc Cancer Res. 2015 Jun 2.Google Scholar
- 14.Cho WC. Exploiting the therapeutic potential of microRNAs in human cancer. Expert Opin Ther Targets. 2012;16:345350.Google Scholar